

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10569315	
	Filing Date		2008-04-28	
	First Named Inventor	Gerard M. Housey		
	Art Unit	1624		
	Examiner Name	Ward, Paul V.		
Attorney Docket Number		00395/45		

U.S.PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	5741641		1998-04-21	Smart et al.	

If you wish to add additional U.S. Patent citation information please click the Add button. [Add](#)

U.S.PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button. [Add](#)

FOREIGN PATENT DOCUMENTS							Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button. [Add](#)

NON-PATENT LITERATURE DOCUMENTS			Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10569315
Filing Date	2008-04-28
First Named Inventor	Gerard M. Housey
Art Unit	1624
Examiner Name	Ward, Paul V.
Attorney Docket Number	00395/45

1	GOHJI, K. et al., "Enhanced inhibition of colony formation of human renal cell carcinoma in soft agar by the combination of alpha difluoromethylomithine and recombinant gamma interferon." Cancer Res. (1986), Vol. 46, pp. 6264-6268.	<input type="checkbox"/>
2	GOODMAN & GILMAN, The Pharmacological Basis of Therapeutics, 9th ed. (1996) Chapter 2.	<input type="checkbox"/>
3	GOTO, R. et al., "Characteristics of D leucine uptake by mouse Ehrlich ascites tumor cells." J. Biochem. (1979) (Tokyo), Vol. 86, pp. 363-369.	<input type="checkbox"/>
4	GOUSTIN, A.S. et al., "Growth factors and cancer." Cancer Res. (1986), Vol. 46, pp. 1015-1029.	<input type="checkbox"/>
5	GROS, P. et al., "Chromosome mediated gene transfer of multidrug resistance." Mol. Cell Biol. (1986), Vol. 6, pp. 3785-3790.	<input type="checkbox"/>
6	GUADAGNO, T.M. et al., "A link between cyclin A expression and adhesion-dependent cell cycle progression." Science (1993), Vol. 262(5139), pp. 1572-5.	<input type="checkbox"/>
7	HAKOMORI, S., "Tumor associated carbohydrate antigens." Annu. Rev. Immunol. (1984), Vol. 2, pp. 103-126.	<input type="checkbox"/>
8	HALLEK, M. et al., "Signal transduction of interleukin-6 involves tyrosine phosphorylation of multiple cytosolic proteins and activation of Src-family kinases Fyn, Hck, and Lyn in multiple myeloma cell lines." Exp Hematol. (1997), Vol. 25 (13), pp. 1367-77.	<input type="checkbox"/>
9	HIBSHOOSH, H. et al., "Effects of overexpression of ornithine decarboxylase (ODC) on growth control and oncogene-induced cell transformation." Oncogene (1991), Vol. 6(5), pp. 739-43.	<input type="checkbox"/>
10	HORI, M. et al., "Antibiotics Inhibiting Oncogene Functions." Gann Monograph on Cancer Research (1989), Vol. 36, pp. 193-201.	<input type="checkbox"/>
11	HOUSEY, G. M., et al. "Isolation and nucleotide sequence analysis of cDNA clones from rat brain using oligonucleotide probes to protein kinase C and protein kinase A." In: Journal of Cellular Biochemistry, Supplement 10C: UCLA Symposia on Molecular & Cellular Biology, Abstract L95, Alan R. Liss, Inc., New York, p. 132, (1986).	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10569315
Filing Date	2008-04-28
First Named Inventor	Gerard M. Housey
Art Unit	1624
Examiner Name	Ward, Paul V.
Attorney Docket Number	00395/45

12	HOUSEY, G.M., et al., "Isolation of cDNA clones encoding protein kinase C: evidence for a protein kinase C related gene family." Proc. Natl. Acad. Sci. USA (1987), Vol. 84, pp. 1065-1069.	<input type="checkbox"/>
13	HOUSEY, G.M. et al., "Structural and functional studies of protein kinase C. Adv. Exp." Med. Biol. (1988), Vol. 234, pp. 127-140.	<input type="checkbox"/>
14	HOUSEY, G.M. et al., "Altered Growth Control and Enhanced Morphologic Response to Tumor Promoters in Rat Fibroblasts Stably Overproducing Protein Kinase C." In: Journal of Cellular Biochemistry, Supplement 12A: UCLA Symposia on Molecular & Cellular Biology, (January 17-January 30, 1988), Abstract C224, Alan R. Liss, Inc., New York, p. 105.	<input type="checkbox"/>
15	HSIAO, W.-L.W. et al., "Oncogene induced transformation of C3H 10T1/2 cells is enhanced by tumor promoters." Science (1984), Vol. 226, pp. 552-555.	<input type="checkbox"/>
16	HSYU, P.H. et al., "Pharmacokinetics and cyclooxygenase inhibition of itazigrel in normal volunteers after single oral doses." J. Pharm. Sci. (1994), Vol. 83, pp. 1747-1750.	<input type="checkbox"/>
17	HUISGEN, R. et al., "Diphenyl-nitrilimin und seine 1,3-dipolaren additionen an alkene und alkine." Tetrahedron (1962), Vol. 17, pp. 3-29. (in German with English abstract)	<input type="checkbox"/>
18	INABA, M. et al., "Reversal of multidrug resistance by non antitumor anthracycline analogs." Gann (1984), Vol. 75, pp. 1049-1052.	<input type="checkbox"/>
19	INGRAM, V.M. "Sequence Methods." Meth. Enzymol. (1963), Vol. 6, pp. 831-848.	<input type="checkbox"/>
20	IKEDA, T. et al., "Anti-allergic and anti-inflammatory actions of 2'-(tetrazole-5-yl) 4-hydroxy-2-methyl-2H-1,2-benzothiazine 1,1-dioxide." Bioorg. Med. Chem. Lett. (1992), Vol. 2, pp. 709-714.	<input type="checkbox"/>
21	JENG, A.Y. et al., "Phosphorylation of ras oncogene product by protein kinase C." Biochem. Biophys. Res. Commun. (1987), Vol. 145, pp. 782-788.	<input type="checkbox"/>
22	JENKINS, F.J. et al., "Effect of ribavirin on Rous sarcoma virus transformation." Antimicrob. Agents Chemother. (1981), Vol. 19, pp. 364-368.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10569315
Filing Date	2008-04-28
First Named Inventor	Gerard M. Housey
Art Unit	1624
Examiner Name	Ward, Paul V.
Attorney Docket Number	00395/45

23	JUNG-TESTAS, I. et al., "Effects of steroid hormones and antihormones in cultured cells." Exp. Clin. Endocrinol. (1985), Vol. 86, pp. 151-164.	<input type="checkbox"/>
24	KAHANA, C. et al., "Isolation of cloned cDNA encoding mammalian ornithine decarboxylase." Proc. Natl. Acad. Sci. USA (1984), Vol. 81, pp. 3645-3649.	<input type="checkbox"/>
25	KAHANA, C. et al., "Nucleotide sequence of murine ornithine decarboxylase mRNA." Proc. Natl. Acad. Sci. USA (1985), Vol. 82, pp. 1673-1677.	<input type="checkbox"/>
26	KAJIKAWA, N. et al., "Ca ²⁺ dependent neutral protease and proteolytic activation of Ca ²⁺ activated, phospholipid dependent protein kinase." Methods. Enzymol. (1983), Vol. 102, pp. 279-290.	<input type="checkbox"/>
27	KAMATA, N. et al., "Growth inhibitory effects of epidermal growth factor and overexpression of its receptors on human squamous cell carcinomas in culture." Cancer Res. (1986), Vol. 46, pp. 1648-1653.	<input type="checkbox"/>
28	KARTNER, N. et al., "Cell surface P glycoprotein associated with multidrug resistance in mammalian cell lines." Science (1983), Vol. 221, pp. 1285-1288.	<input type="checkbox"/>
29	KARTNER, N. et al., "Detection of P glycoprotein in multidrug resistant cell lines by monoclonal antibodies." Nature (1985), Vol. 316(6031), pp. 820-823.	<input type="checkbox"/>
30	KAVANAGH, T.J. et al., "Characterization of a human teratocarcinoma cell assay for inhibitors of metabolic cooperation." Cancer Res. (1986), Vol. 46, pp. 1359-1366.	<input type="checkbox"/>
31	KIKKAWA, U. et al., "Protein Kinase C and the Mechanism of Action of Tumor Promoters." In Levine, A.J. et al. (Eds), Cancer Cells 1: The Transformed Phenotype, pp. 239-244. (Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. 1984).	<input type="checkbox"/>
32	KIRSTEIN et al. "Tumor necrosis factor stimulates proliferation of human gastrosarcoma cells and transcription of Myc messenger RNA." UCLA Symposia on Molecular & Cellular Biology Abstract D 209, January 17-January 30, 1988.	<input type="checkbox"/>
33	KLATZMANN, D. et al., "HIV infection: facts and hypotheses." Immunol. Today (1986), Vol. 7, pp. 291-296.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10569315
Filing Date	2008-04-28
First Named Inventor	Gerard M. Housey
Art Unit	1624
Examiner Name	Ward, Paul V.
Attorney Docket Number	00395/45

34	KLATZMANN, D. et al., "T lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV." Nature (1984), Vol. 312(5996), pp. 767-768.	<input type="checkbox"/>
35	KNOWLES, P.P. et al., "Purification of immunotoxins containing ricin A chain and abrin A chain using blue sepharose CL 6B." Anal. Biochem. (1987), Vol. 160, pp. 440-443.	<input type="checkbox"/>
36	KOENIG, S. et al., "Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy." Science (1986), Vol. 233(4768), pp. 1089-1093.	<input type="checkbox"/>
37	KOHLER, G. et al., "Derivation of specific antibody producing tissue culture and tumor lines by cell fusion." Eur. J. Immunol. (1976), Vol. 6, pp. 511-519.	<input type="checkbox"/>
38	KOPROWSKI, H. et al., "Human anti idotype antibodies in cancer patients: Is the modulation of the immune response beneficial for the patient?" Proc. Natl. Acad. Sci. USA (1984), Vol. 81, pp. 216-219.	<input type="checkbox"/>
39	KRAFT, A.S. et al., "Overexpression of protein kinase C beta 1 is not sufficient to induce factor independence in the interleukin-3-dependent myeloid cell line FDC-P1." Oncogene (1990), Vol. 5(8), pp. 1243-6.	<input type="checkbox"/>
40	KRAUSS, R.S. et al., "Disturbances in growth control and gene expression in a C3H/10T1/2 cell line that stably overproduces protein kinase C." Oncogene (1989), Vol. 4, pp. 991-998.	<input type="checkbox"/>
41	KRONKE, M. et al., "Adult T cell leukemia: a potential target for ricin A chain immunotoxins." Blood (1985), Vol. 65, pp. 1416-1421.	<input type="checkbox"/>
42	KRONKE, M. et al., "Selective killing of human T lymphotropic virus I infected leukemic T cells by monoclonal anti interleukin 2 receptor antibody ricin A chain conjugates: potentiation by ammonium chloride and monensin." Cancer Res. (1986), Vol. 46, pp. 3295-3298.	<input type="checkbox"/>
43	KUCZEK, T. et al., "Tumor cell heterogeneity: divided colony assay for measuring drug response." Proc. Natl. Acad. Sci. USA (1987), Vol. 84, pp. 4490-4494.	<input type="checkbox"/>
44	KUWANO, M. et al., "Techniques to reverse or circumvent drug resistance in vitro." Prog. Clin. Biol. Res. (1986), Vol. 223, pp. 163-171.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10569315
Filing Date		2008-04-28
First Named Inventor	Gerard M. Housey	
Art Unit	1624	
Examiner Name	Ward, Paul V.	
Attorney Docket Number	00395/45	

45	LANE, H.C. et al., "Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome. Evidence for a selective defect in soluble antigen recognition." N. Engl. J. Med. (1985), Vol. 313, pp. 79-84.	<input type="checkbox"/>
46	LANE, H.C. et al., "Abnormalities of B cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome." N. Engl. J. Med. (1983), Vol. 309, pp. 453-458.	<input type="checkbox"/>
47	LANGER, R. "Controlled release of macromolecules." Chemtech (1982), Vol. 12, pp. 98-105.	<input type="checkbox"/>
48	LASKY, L.A. et al., "Neutralization of the AIDS retrovirus by antibodies to a recombinant envelope glycoprotein." Science (1986) , Vol. 233(4760), pp. 209-212.	<input type="checkbox"/>
49	LERNER, R.A. "Tapping the immunological repertoire to produce antibodies of predetermined specificity." Nature (1982), Vol. 299(5884), pp. 592-596.	<input type="checkbox"/>
50	LESTER, H.A., "Heterologous expression of excitability proteins: route to more specific drugs?" Science(1988), Vol. 241(4869), pp. 1057-1063.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button **Add**

EXAMINER SIGNATURE

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10569315
Filing Date	2008-04-28
First Named Inventor	Gerard M. Housey
Art Unit	1624
Examiner Name	Ward, Paul V.
Attorney Docket Number	00395/45

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

- ☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

- ☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

- ☐ See attached certification statement.
- ☐ The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

- ☒ A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Lawrence P. Casson/	Date (YYYY-MM-DD)	2011-11-21
Name/Print	Lawrence P. Casson	Registration Number	46606

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.